Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 vs Intensive Chemotherapy in de Novo AML
NCT05260528Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- May 2023
- Primary completion
- Aug 2028
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), sponsored by Centre Hospitalier Universitaire de Nice. Started May 2023; status: recruiting.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05260528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05260528.